PTT-A: what the research shows
An experimental peptide targeting four hormone receptors. Its weight and muscle findings are from animals so far.
Also known as Experimental peptide tetra-agonist
At a glance
Animal data
Human body-weight loss is not established
21-day rat experiment · conference abstract · not a human trial
An investigational peptide, not an approved medicine. The cited efficacy findings are from cell and rodent experiments, not human weight-loss trials.
What is PTT-A?
PTT-A is a research name for a long-acting peptide developed by Pep2Tango. It is designed to activate GLP-1, GIP, amylin and calcitonin receptors in one molecule. The company’s launch announcement described work preparing candidates for clinical development.
How does PTT-A work?
The proposed approach combines several hormone signals rather than using a single receptor. Early studies tested receptor activity in cells and metabolic effects in rodents. Four targets alone do not establish how effective or tolerable a medicine will be in people.
What does the research show?
- An ADA 2025 conference abstract reported a 21-day experiment in diet-induced obese rats, comparing PTT-A with tirzepatide and a vehicle control.
- Researchers reported fat-mass reduction with preserved muscle measures in the PTT-A groups. This is an animal finding, not proof of muscle preservation in people.
- The cited sources do not provide an average human body-weight-loss percentage or a human comparison with retatrutide.
How do the weight-loss results compare?
Each medicine compared with a placebo in its own trial. Ordered by reported average; this is not a head-to-head ranking.
- Medicine
- Placebo
Retatrutide · Experimental
12 mg weekly
Phase 2 · 48 weeks · 338 people
Tirzepatide · Approved
15 mg weekly (Zepbound)
SURMOUNT-1 · 72 weeks · 2,539 people
Semaglutide · Approved
2.4 mg weekly injection (Wegovy)
STEP 1 · 68 weeks · 1,961 people
Semaglutide · Approved (US)
25 mg daily pill (Wegovy pill)
OASIS 4 · 64 weeks · 307 people
Average body weight lost
Each human trial had different people, doses and lengths, so compare with care. The bars describe approved or experimental medicines studied under medical supervision with diet and exercise advice, not laboratory research products. They use full journal reports; conference findings and different endpoints appear separately below.
Show these numbers as a table
| Medicine | Trial | People | Weeks | Medicine | Placebo | Source |
|---|---|---|---|---|---|---|
| Retatrutide, 12 mg weekly | Phase 2 | 338 | 48 | 24.2% | 2.1% | PubMed |
| Tirzepatide, 15 mg weekly (Zepbound) | SURMOUNT-1 | 2,539 | 72 | 20.9% | 3.1% | PubMed |
| Semaglutide, 2.4 mg weekly injection (Wegovy) | STEP 1 | 1,961 | 68 | 14.9% | 2.4% | PubMed |
| Semaglutide, 25 mg daily pill (Wegovy pill) | OASIS 4 | 307 | 64 | 13.6% | 2.2% | PubMed |
PTT-A and CBL-514: evidence so far
Neither has a comparable average human body-weight-loss result in the research below. Animal body weight and human fat volume measure different things, so they are shown separately from the bars.
Animal research · conference abstract
PTT-A
- Average human body-weight loss
- Not established in the cited research
- What was measured
- Body weight in diet-induced obese rats over 21 days
- Reported finding
- Body weight was 19.2% lower versus vehicle at the higher studied exposure; tirzepatide was 12.1% lower versus vehicle in the same experiment.
A difference versus vehicle in rats is not average weight lost by people. It cannot establish superiority to retatrutide in humans.
Human fat-volume subgroup · conference report
CBL-514
- Average human body-weight loss
- Not established by this fat-volume result
- What was measured
- MRI-measured visceral-fat volume, four weeks after final treatment
- Reported finding
- Visceral-fat volume fell 12.01%; placebo rose 5.68%. The small phase 2 subgroup had 40 participants with later follow-up data.
12.01% less visceral fat is not 12.01% less body weight. CBL-514 is an experimental small molecule, not a peptide.
Known risks and side effects
- Human effectiveness, adverse effects and long-term safety cannot be established from these animal experiments.
- Products sold under a research name cannot be assumed to match the developer’s investigational material.
Is PTT-A approved?
Mostly studied in cells and animals, with little or no proper testing in people.
An investigational peptide, not an approved medicine. The cited efficacy findings are from cell and rodent experiments, not human weight-loss trials.
From the community
Watch: PTT-A and related science
We have not selected a reliable dedicated PTT-A video. These lessons cover the relevant biology and research methods; the compound-specific evidence is in the sources below.
Ohio State Wexner Medical Center
What is a GLP-1 agonist, and how does it work?
A hospital explainer of GLP-1 signalling, appetite and blood-sugar regulation.
Allison L. Rhodes, MD · obesity medicine
Related biology
Background on GLP-1 signalling for understanding PTT-A. It does not demonstrate benefits of this compound or formulation.
National Institute of Mental Health
What is clinical research?
Why studies in people are needed and what clinical research is designed to establish.
NIMH · US National Institutes of Health
Research skills
Helps you judge the study design or uncertainty in PTT-A research; it is not a trial of the compound.
National Institute of Mental Health
Different types of clinical research
An introduction to the different questions and designs used in studies involving people.
NIMH · US National Institutes of Health
Research skills
Helps you judge the study design or uncertainty in PTT-A research; it is not a trial of the compound.
Sources and references
- PTT-A tetra-agonist compared with tirzepatide in diet-induced obese rats (85-OR)Ghosh et al. · Diabetes · ADA conference abstract · 2025
- Discovery of long-acting peptide tetra-agonists in animal models of obesity (299-OR)Diabetes · ADA conference abstract · 2024
- Versant Ventures unveils Pep2Tango TherapeuticsOriginal company launch announcement · November 21, 2024 (PDF)
VETUD Learn explains published research in plain language. It is general information, not medical advice. Talk to a doctor before starting, stopping or changing any treatment.
In the research shop
Check the catalog for related laboratory research materials. These products are separate from the approved medicines and clinical trial formulations discussed here.
Checking regional availability…
